Molecular mechanisms of immunoglobulin E regulation

International Archives of Allergy and Immunology

Volumn 115, Issue 4, 1998, Pages 257-269

  Bacharier, Leonard B ^a   Jabara, Haifa ^a   Geha, Raif S ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

IgE; Interleukin 13; Interleukin 4; Isotype switching

Indexed keywords

IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4;

B LYMPHOCYTE; GENE REARRANGEMENT; IMMUNOGLOBULIN PRODUCTION; IMMUNOREGULATION; PRIORITY JOURNAL; REVIEW;

ANTI-ASTHMATIC AGENTS; ANTIGENS, CD40; B-LYMPHOCYTES; DNA NUCLEOTIDYLTRANSFERASES; GENE REARRANGEMENT; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN E; INTERLEUKIN-13; INTERLEUKIN-4; SIGNAL TRANSDUCTION; VDJ RECOMBINASES;

EID: 0031937852     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069456     Document Type: Review

References (128)

1. Janeway CA Jr, Travers P: Immunobiology: The immune system in health and disease. New York. Garland, 1994, pp 3:15-3:35.
2. Schwartz RS: Jumping genes and the immunoglobulin V gene system. N Engl J Med 1995; 333:42-44.
3. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE: RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992;68:869-877.
4. Shikai Y, Rathbun G, Lam K-P, Oltz EM, Stewart V, Mendelsohn M, Charron J, Datta M, Young F, Stall AM, Alt FW: RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992; 68:855-867.
5. Schwartz K, Gauss GH, Ludwig L, Pannicke U, Li Z, Lidner D, Friedrich W, Seger RA, Hansen-Hagge TE, Desiderio S, Lieber MR, Bartram CR: RAG mutations in human B cell-negative SCID. Science 1996;274:97-99.
6. Nikaido T, Yamawaki KY, Honjo T: Nucleotide sequences of switch regions of immunoglobulin Cε and Cγ genes and their comparison. J Biol Chem 1982;257:7322-7329.
7. Shapira SK, Jabara HH, Thienes CP, Ahern DJ, Vercelli D, Gould HJ, Geha RS: Deletional switch recombination occurs in interlcukin-4-induced isotype switching to IgE expression by human B cells. Proc Natl Acad Sci USA 1991; 88:7528-7532.
8. Shapira SK, Vercelli D, Jabara HH, Fu SM, Geha RS: Molecular analysis of the induction of immunoglobulin E synthesis by human B cells by interleukin-4 and engagement of CD40 antigen. J Exp Med 1992;175:289-292.
9. Vercelli D, Jabara HH, Arai K-I, Geha RS: Induction of human IgE synthesis requires interleukin-4 and T/B interactions involving the T-cell receptor/CD3 complex and MHC class II antigens. J Exp Med 1989;169:1295-1307.
10. Vercelli D, Jabara HH, Lauener RP, Geha RS: IL-4 inhibits the synthesis of IFN-γ and induces the synthesis of IgE in human mixed lymphocyte cultures. J Immunol 1990;144:570-573.
11. Clark EA, Ledbetter JA: How B and T cells talk to each other. Nature 1994;367:425-428.
12. Del Prete G, Maggi E, Parronchi P, Chretien I, Tiri A, Macchia D, Ricci M, Banchercau J, de Vries J, Romagnani S: IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cells clones and their supernatants. J Immunol 1988;140:4193-4198.
13. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S: The CD40 antigen and its ligand. Annu Rev Immunol 1994;12:881-922.
14. + T-cell responses. Immunol Today 1996;17:410-414.
15. Janeway CA, Bottomly K: Signals and signs for lymphocyte responses. Cell 1994;76:275-285.
16. Jabara HH, Fu SM, Geha RS, Vercelli D: CD40 and IgE: Synergism between anti-CD40 monoclonal antibody and interleukin-4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med 1990;172:1861-1864.
17. Fanslow WC, Anderson DM, Grabstein KH, Clark EA, Cosman D, Armitage RJ: Soluble forms of CD40 inhibit biological responses of human B cells. J Immunol 1992;149:655-660.
18. Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins Na, Copeland NG, Bedell MA, Edelhoff S, Disteche CM, Simoneaux DK, Fanslow WC, Belmont J, Spriggs MK: CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993;259:990-993.
19. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, Stenkamp R, Neubauer M, Roberts RL, Noelle RJ, Ledbetter JA, Francke U, Ochs HD: The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993; 72:291-300.
20. Fuleihan R, Ramesh N, Loh R, Jabara H, Rosen FS, Chatila T, Fu SM, Stamekovic I, Geha RS: Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci USA 1993;90:2170-2173.
21. DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G: CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature 1993;361:541-543.
22. Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, Ugazio AG, Notarangelo LD, Levinsky RJ, Kroczek RA: Defective expression of CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993; 361:539-541.
23. Xu J, Foy TM, Laman JD, Elliott EA, Dunn JJ, Waldschmidt TJ, Elsemore J, Noelle RJ, Falvell RA: Mice deficient for CD40 ligand. Immunity 1994;1:423-431.
24. Castigli E, Alt FW, Davidson L, Bottaro A, Mizoguchi E, Bhan AK, Geha RS: CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc Natl Acad Sci USA 1994;91:12135-12139.
25. Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T, Kikutani H: The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation. Immunity 1994;1:167-178.
26. Gauchat J-F, Lebman DA, Coffman RL, Gascan H, de Vries JE: Structure and expression of germline ε transcripts in human B cells induced by interleukin-4 to switch to IgE production. J Exp Med 1990;172:463-473.
27. Punnonen J, Aversa G, Cocks BG, McKenzie ANJ, Menon S, Zurawski G, Malefyt R, de Vries JE: Interleukin-13 induces interleukin-4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993;90:3730-3734.
28. Snapper CM, Marcu KB, Zelazowski P: The immunoglobulin class switch: Beyond 'accessibility'. Immunity 1997;6:217-223.
29. Ballantyne J, Henry DL, Marcu KB: Antibody class switch recombinase activity in B-cell stage-specific and functions stoachastically in the absence of 'targeted acessibility' control. Int Immunol 1997;9:963-974.
30. Bottaro A, Lansford R, Xu L, Zhang J, Rothman P, Alt FW: S region transcription per se promotes basal IgE class switch recombination but additional factors regulate the efficiency of the process. EMBO 1994;13:665-674.
31. Snapper CM, Mond JJ: Towards a comprehensive view of immunoglobulin class switching. Immunol Today 1993;14:15-17.
32. Blunt T, Finnie NJ, Taccioli GE, Smith G, Demengeot J, Gottlieb TM, Mizuta R, Varghese AJ, Alt FW, Jeggo PA, Jackson SP: Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation. Cell 1995;80:813-823.
33. Weaver DT: What to do at an end: DNA double-strand break repair. Trends Genet 1995;11:388-392.
34. Roth DB, Lindahl T, Gellert M: How to make ends meet. Curr Biol 1995;5:496-499.
35. Rolink A, Melchers F, Andersson J: The SCID but not the RAG-2 gene product is required for Sυ-Sε heavy chain class switching. Immunity 1996;5:319-330.
36. Zelazowski P, May EE, Kehry MR, Snapper CM: Regulation of Ku expression in normal murine B cells by stimuli that promote switch recombination. J Immunol 1997;159:2559-2562.
37. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature 1996; 383:787-793.
38. Xu L, Rothman P: IFN-γ represses ε germline transcription and subsequently downregulates switch recombination to ε. Int Immunol 1994;6: 515-521.
39. Defrance T, Carayon P, Billian G, Guillemot J-C, Minty A, Caput D, Ferrara P: Interleukin-13 is a B-cell stimulating factor. J Exp Med 1994;179:135-143.
40. DeKruyff RH, Turner T, Abrams JS, Palladino MA, Umetsu DT: Induction of human IgE synthesis by CD4+ T-cell clones. J Exp Med 1989; 170:1477-1493.
41. Pene J, Rousset F, Briere F, Chretien I, Paliard X, Banchereau J, Spits H, de Vries JE: IgE production by normal human B cells induced by alloreactive T-cell clones is mediated by IL-4 and suppressed by IFN-γ. J Immunol 1988;141: 1218-1224.
42. Finkelman FD, Katona IM, Urban JF, Snapper CM, Ohara J, Paul WE: Supression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1. Proc Natl Acad Sci USA 1986;83:9675-9678.
43. Finkelman FD, Urban JF, Beckmann MP, Schooley KA, Holmes JM, Katona IM: Regulation of murine in vivo IgG and IgE responses by a monoclonal anti-IL-4 receptor antibody. Int Immunol 1991;3:599-607
44. Garrone P, Djossou O, Galizzi J-P, Banchereau J: A recombinant extracellular domain of the human interleukin-4 receptor inhibits the biological effects of interleukin-4 on T and B lymphocytes. Eur J Immunol 1991;21:1365-1369.
45. Gessner A, Schroppel K, Will A, Enssle KH, Lauffer L, Rollinghoff M: Recombinant soluble interleukin-4 (IL-4) receptor acts as an antagonist of IL-4 in murine cutaneous Leishmaniasis. Infect Immun 1994;62:4112-4117.
46. Ryan JJ: Interleukin-4 and its receptor: Essential mediators of the allergic response. J Allergy Clin Immunol 1997;99:1-5.
47. Ho I-C, Hodge MR, Rooney JW, Glimcher LH: The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 1996;85:973-983.
48. Hodge MR, Chun HJ, Rengarajan J, Alt A, Lieberson R, Glimcher LH: NF-AT-driven interleukin-4 transcription potentiated by NIP45. Science 1996;274:1903-1905.
49. Keegan AD, Nelms K, Wang L-M, Pierce JH, Paul WE: Interleukin-4 receptor: Signaling mechanisms. Immunol Today 1994;15:423-432.
50. McKenzie ANJ, Culpepper JA, de Waal Malefyt R, Briere F, Punnonen J, Aversa G, Sato A, Dang W, Cocks BG, de Vries JE, Banchereau J, Zurawski G: Interleukin-13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA 1993;90: 3735-3739.
51. Ihle JN: Cytokine receptor signalling. Nature 1995;377:591-594.
52. Mosley B, Beckmann MP, March CJ, Idzerda RL, Gimpel SD, Van den Bos T, Friend D, Alpert A, Anderson D, Jackson J, Wignall JM, Smith C, Gallis B, Sims JE, Urdal D, Widmer MB, Cosman D, Park LS: The murine interleukin-4 receptor: Molecular cloning and characterization of secreted and membrane-bound forms. Cell 1989;59:335-348.
53. Schulte T, Kurrle R, Rollinghoff M, Gessner A: Molecular characterization and functional analysis of murine interleukin-4 receptor allotypes. J Exp Med 1997;186:1419-1429.
54. Zurawski Sm, Chomarat P, Djossou O, Bidaud C, McKenzie ANJ, Miossec P, Banchereau J, Zurawski G: The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J Biol Chem 1995;270:13869-13878.
55. Caput D, Laurent P, Kaghad M, Lelias J-M, Lefort S, Vita N, Ferrara P: Cloning and characterization of a specific interleukin(IL)-13 binding protein structurally related to the IL-5 receptor α chain. J Biol Chem 1996;271:16921-16926.
56. Hilton DJ, Zhang J-G, Metcalf D, Alexander WS, Nicola NA, Willson TA: Cloning and characterization of a binding subunit of the interleukin-13 receptor that is also a component of the interleukin-4 receptor. Proc Natl Acad Sci USA 1996;93:497-501.
57. Gauchat JF, Schlagenhauf E, Feng NP, Moser R, Yamage M, Jeannin P, Alouani S, Elson G, Notarangelo LD, Wells T, Eugster HP, Bonnefoy JY: A novel 4-kb interleukin-13 receptor alpha mRNA expressed in human B, T, and endothelial cells encoding an alternate type-II interleukin-4/interleukin-13 receptor. Eur J Immunol 1997;27:971-978.
58. Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, Liu ET, Ihle JN: Involvement of the Jak-3 Januse kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 1994;370:153-157.
59. Rolling C, Treton D, Beckmann P, Galanaud P, Richard Y: JAK3 associates with the interleukin-4 receptor and is tyrosine phosphorylated following receptor triggering. Oncogene 1995: 10:1757-1761.
60. Schindler C, Kashleva H, Pernis A, Pine R, Rothman P: STF-IL-4: A novel IL-4-induced signal transducing factor. EMBO J 1994;13: 1350-1356.
61. Ivashkiv LB: Cytokincs and STATs: How can signals achieve specificity? Immunity 1995;3: 1-4.
62. Schindler U, Wu P, Rothe M, Brasseur M, McKnight SL: Components of a Stat recognition code: Evidence for two layers of molecular selectivity. Immunity 1995;2:689-697.
63. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle FW, Nosaka T, Vignali DAA, Doherty PC, Grosveld G, Paul WE, Ihle JN: Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996; 380:630-633.
64. Takeda K, Kamanaka M, Tanaka T, Kishimoto T, Akira S: Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J Immunol 1996;157:3220-3222
65. Palmer-Crocker PL, Hughes CWH, Pober JS: IL-4 and IL-13 activate the JAK2 tyrosine kinase and STAT6 in cultured human vascular endothelial cells through a common pathway that does not involve the γc chain. J Clin Invest 1996;98:604-609.
66. Keegan AD, Johnston JA, Tortolani PJ, McReynolds LJ, Kinzer C, O'Shea JJ, Paul WE: Similaritis and differences in signal transduction by interleukin-4 and interleukin-13: Analysis of Janus kinase activation. J Biol Chem 1995;92: 7681-7685.
67. Welham MJ, Learmonth L, Bone H, Schrader JW: Interleukin-13 signal transduction in lymphohemopoietic cells. J Biol Chem 1995;270: 12286-12296.
68. Izuhara K, Keike T, Otsuka T, Yamaoka K, Mayumi M, Imamura T, Niho Y, Harada N: Signal transduction pathway of interleukin-4 and interleukin-13 in human B cells derived from X-linked severe combined immunodeficiency patients. J Biol Chem 1996;271:619-622.
69. Wang L-M, Myers MG, Sun X-J, Aaronson SA, White M, Peirce JH: IRS-I: essential for insulin- and IL-4-stimulated mitogenesis in hematopoietic cells. Science 1993;261:1591-1594.
70. Burfoot MS, Rogers NC, Watling D, Smith JM, Pons S, Paonessaw G, Pellegrini S, White MF, Kerr IM: Janus kinase-dependent activation of insulin receptor substrate I in response to interleukin-4, oncostatin M, and the interferons. J Biol Chem 1997;272:24183-24190.
71. Imani F, Rager KJ, Catipovic B, Marsh DG: Interleukin-4 (IL-4) induces phosphatidylinositol 3-kinase (p85) dephosphorylation. J Biol Chem 1997;272:7927-7931.
72. Hershey GKK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA: The association of atopy with a gain-of-function mutation in the α subunit of the interleukin-4 receptor. N Engl J Med 1997;337:1720-1725.
73. Delphin S, Stavnezer J: Characterization of an interleukin-4 (IL-4)-responsive region in the immunoglobulin heavy chain germline ε promoter: Regulation by NF-IL-4, a c/ebp family member and NF-NB/p50. J Exp Med 1995;181: 181-192.
74. H transcription, and Ig class switching. J Immunol 1996;156:183-191.
75. H, transcription and Ig class switching. J Immunol 1997; 159:3133-3139.
76. Thienes CP, DeMonte L, Monticclli S, Buddlinger M, Gould HJ, Vercelli D: The transcription factor B cell-specific activator protein (BSAP) enhances both IL-4- and CD40-mediated activation of the human ε germline promoter. J Immunol 1997;158:5874-5882.
77. c chain. Eur J Immunol 1997;27:116-121.
78. Fujiwara H, Hanissian SH, Tsytsykova A, Geha RS: Homodimerization of the human interleukin-4 receptor α chain induces Cε germline transcripts in B cells in the absence of the interleukin-2 receptor γ chain. Proc Natl Acad Sci USA 1997;94:5866-5871.
79. Purkerson JM, Isakson PC: Interleukin-5 (IL-5) provides a signal that is required in addition to IL-4 for isotype switching to immunoglobulin (Ig) Gl and IgE. J Exp Med 1992;175:973-982.
80. Vercelli D, Jabara HH, Arai K-I, Yokota T, Geha RS: Endogenous interleukin-6 plays an obligatory role in interleukin-4-dependent human IgE synthesis. Eur J Immunol 1989;19:1419-1424.
81. Kiniwa M, Gately M, Gubler U, Chizzonite R, Fargeas C, Delespesse G: Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes. J Clin Invest 1992;90:262-266.
82. Yoshimoto T, Okamura H, Tagawa Y-I, Iwakura Y, Nakanishi K: Interleukin-18 together with interleukin-12 inhibits IgE production by induction of interferon-γ production from activated B cells. Proc Natl Acad Sci USA 1997;94: 3948-3953.
83. Stamenkovic I, Clark EA, Seed B: A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 1989;8:1403-1410.
84. Worm M, Geha RS: CD40 ligation induces lymphotoxin α gene expression in human B cells. Int Immunol 1994;6:1883-1890.
85. Cheng G, Cleary AM, Ye Z, Hong DI, Lederman S, Baltimore D: Involvement of CRAFI, a relative of TRAF, in CD40 signaling. Science 1995;267:1494-1498.
86. Ishida T, Tojo T, Aoki T, Kohayashi N, Ohishi T, Watanabe Y, Yamamoto T, Inoue J: TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci USA 1996;93:9437-9442.
87. Ishida T, Mizushima S, Azuma S, Kobayashi N, Tojo T, Suzuki K, Aizawa S, Watanabe T, Mosialos G, Kieff E, Yamamoto T, Inoue J: Identification of TRAF6, a novel tumor necrosis factor receptor-associated protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem 1996;271:28745-28748.
88. Mosialos G, Birkenbach M, Yalamanchili R, Van Arsdale T, Ware C, Kieff E: The Epstein-Barr virus transforming protein LMP-1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995;80:389-399.
89. Nakano H, Oshima H, Chung W, Williams-Abbott L, Ware CF, Yagita H, Okumura K: TRAF5, an activator of NK-NB and putative signal transducer for the lymphotoxin-β receptor. J Biol Chem 1996;271:14661-14664.
90. Rothe M, Sarma V, Dixit VM, Goeddel DV: TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science 1995;269: 1424-1427.
91. Xu Y, Cheng G, Baltimore D: Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity 1996;5:407-415.
92. Ren CL, Morio T, Fu SM, Geha RS: Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2. J Exp Med 1994;179:673-680.
93. Faris M, Gaskin F, Geha RS, Fu SM: Tyrosine phosphorylation defines a unique transduction pathway in human B cells mediated via CD40. Trans Assoc Am Physicians 1993;106:187-195.
94. Loh RK, Jahara HH, Ren CL, Fu SM, Vercelli D, Geha RS: Role of protein tyrosine kinases and phosphatases in isotype switching: Cross-linking CD45 to CD40 inhibits IgE isotype switching in human B cells. Immunol Lett 1995;45:99-106.
95. Loh RK, Jabara HH, Ren CL, Fu SM, Geha RS: Role of protein tyrosine kinases in CD40/ interleukin-4-mediated isotype switching to IgE. J Allergy Clin Immunol 1994;94:784-792.
96. Faris M, Gaskin F, Parsons JT, Fu SM: CD40 signaling pathway: Anti-CD40 monoclonal antibody induces rapid dephosphorylation and phosphorylation of tyrosine-phosphorylated proteins including protein tyrosine kinase Lyn, Fyn, and Syk and the appearance of a 28-kD tyrosine phosphorylated protein. J Exp Med 1994;179:1923-1931.
97. Ihle JN: The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv Immunol 1995;60:1-28.
98. Hanissian SH, Geha RS: Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity 1997; 6:379-388.
99. Berberich I, Shu GL, Clark EA: Cross-linking CD40 on B cells rapidly activated nucelar factor-NB. J Immunol 1994;153:4357-4366.
100. Messner B, Stutz AM, Albrecht B, Peiritsch S, Woisetschlager M: Cooperation of binding sites for STAT6 and NFNB/rel in the IL-4-induced up-regulation of the human IgE germ-line promoter. J Immunol 1997;159:3330-3337.
101. Iciek LA, Delphin SA, Stavnezer J: CD40 cross-linking induces Igε germline transcripts in B cells via activation of NF-NB. J Immunol 1997;158:4769-4779.
102. Thyphronitis G, Tsokos GC, June CH, Levine AD, Finkelman FD: IgE secretion by Epstein-Barr virus-infected purified human B lymphocytes is stimulated by interleukin-4 and suppressed by interferon γ. Proc Natl Acad Sci USA 1989;86:5580.
103. Jabara HH, Schneider LC, Shapira SK, Alfieri C, Moody CT, Kieff E, Geha RS, Vercelli D: Induction of germ-line and mature Cε transcripts in human B cells stimulated with RIL-4 and EBV. J Immunol 1990;145:3468-3473.
104. Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E, Mosialos G: Tumor necrosis factor receptor associated factor 2 is a mediator of NF-NB activation by latent membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci USA 1997;93:11085-11090.
105. Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, Mosialos G: Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: Role in NF-kappaB activation. Mol Cell Biol 1996;16:7098-7108.
106. Jabara HH, Ahern DJ, Vercelli D, Geha RS: Hydrocortisone and IL-4 induce IgE isotype switching in human B cells. J Immunol 1991; 147:1557-1560.
107. Kruse N, Tony H-P, Sebald W: Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid substitution. EMBO J 1992;11:3237-3244.
108. Zurawski SM, Veja F, Huyghe B, Zurawski G: Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J 1993;12:2663-2670.
109. Aversa G, Punonnen J, Cocks BG, de Waal Malefyt R, Vega F, Zurawski SM, Zurawski G, de Vries JE: An interleukin-4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4)and IgE synthesis and B-cell proliferation: Support for a common component shared by IL-4 and IL-13 receptors. J Exp Med 1993;178:2213-2218.
110. Carballido JM, Schols D, Namikawa R, Zurawski S, Zurawski G, Roncarolo M-G, de Vries JE: IL-4 induces human B-cell maturation and IgE synthesis in SCID-hu mice. J Immunol 1995;155:4162-4170.
111. Atamas SP, Choi J, Yurovsky VV, White B: An alternative splice variant of human IL-4. IL-4δ2, inhibits IL-4-stimulated T-cell proliferation. J Immunol 1996;156:435-441.
112. Sato TA, Widmer MB, Finkelman FD, Madani H, Jacobs CA, Grabstein KH, Miliszewski CR: Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 1993;150:2717-2723.
113. Zhang J-G, Hilton DJ, Wilson TA, McFarlane C, Roberts BA, Moritz RL, Simpson RJ, Alexander WS, Metcalf D, Nicola NA: Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. J Biol Chem 1997;272:9474-9480.
114. Kuhn R, Rajewsky K, Muller W: Generation and analysis of interleukin-4-deficient mice. Science 1991;254:707-710.
115. Boguniewicz M, Jaffe HS, Izu A, Sullivan MJ, York D, Geha RS, Leung DYM: Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am J Med 1990;88:365-370.
116. Hanifin JM, Schneider LC, Leung DYM, Ellis CN, Jaffe HS, Izu AE, Bucalo LR, Hirabayashi SE, Tofte SJ, Cantu-Gonzales G, Milgrom H, Boguniewicz M, Cooper KD: Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993;28:189-197
117. Reinhold U, Kukel S, Brzoska J, Kreysel HW: Systemic interferon gamma treatment in severe atopic dermatitis. J Am Acad Dermatol 1993;29:58-63.
118. Vercelli D, Jabara HH, Cunningham-Rundles C, Abrams JS, Lewis DB, Meyer J, Schneider LC, Leung DYM, Geha RS: Regulation of immunoglobulin (Ig)E synthesis in the hyper-IgE syndrome. J Clin Invest 1990;85:1666-1671.
119. 389IL-4. J Allergy Clin Immunol 1995;95:893-900.
120. Geha RS, Helm B, Gould H: Inhibition of the Pausnitz-Kustner reaction by an immunoglobulin ε-chain fragment synthesized by E. coli. Nature 1985;315:577-578.
121. Haak-Frendscho M, Ridgway J, Shields R, Robbins K, Gorman C, Jardieu P: Human IgE receptor α-chain IgG chimera blocks passive cutaneous anaphylaxis reaction in vivo. J Immunol 1993;151:351-358.
122. Wiegand TW, Williams PB, Dreskin SC, Jouvin M-H, Kinet J-P, Tasset D: High-affinity oligonucleotide ligands to human IgE inhibit binding to the Fcε receptor I. J Immunol 1996; 157:221-230.
123. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Frendly BM, Jardieu PM: Humanization of an antibody directed against IgE. J Immunol 1993;151:2623-2632.
124. MacGlashan DW, Bochner BS, Adelams DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM: Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-1445.
125. Corne J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B, Gygax D, Heusser C, Patalano F, Richardson W, Kilchher E, Staehelin T, Davis F, Gordon W, Sun L, Liou R, Wang G, Chang T-W, Holgate S: The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics. J Clin Invest 1997;99:879-887.
126. Davis FM, Gossett LA, Chang TW: An epitope on membrane-bound but not secreted IgE: Implications in isotype-switching regulation. Biotechnology 1991;9:53-56.
127. Loh RK, Jabara HH, Geha RS: Disodium cromoglycate inhibits S mu → S epsilon deletional switch recombination and IgE synthesis in human B cells. J Exp Med 1994;180:663-671.
128. Loh RK, Jabara HH, Geha RS: Mechanisms of inhibition of IgE synthesis by nedocromil sodium: Nedocromil sodium inhibits deletional switch recombination in human B cells. J Allergy Clin Immunol 1996;97:1141-1150.